GlobeNewswire

AB Linas Agro Group boosts sales revenue and profits in first half of the financial year 2020/21

Share

Consolidated revenue went 50% up to EUR 475 million. Sales volume in tons reached 1.7 million and was 55% more as compared to previous year.

The gross profit reached EUR 20.0 million and was 1% higher than a year before. Consolidated EBITDA was 46% higher and amounted to EUR 13.4 million. The operating profit was EUR 5 million or 67% higher.
Profit before taxes increased from to EUR 1.7 million to EUR 3.9 million. The net profit attributable to the company went up from EUR 1.5 million to EUR 3.7 million.

A commentary by Mažvydas Šileika, Financial Director of AB Linas Agro Group:

Revenue from trade in grain, oilseeds and feedstuff increased by 73% over the year to EUR 351 million, and operating profit amounted to EUR 0.9 million being 55% lower. Higher sales of traditional products, like wheat, rapeseed and barley, as well as increased feedstuffs merchandising were the factors affecting revenue growth. Business profitability was lower due to seasonality of trading activities.

A good harvest has had a significant impact on products and services for farming business that generated EUR 83 million or 19% higher income and 132% higher operating profit – EUR 4.3 million. Sales of seeds and plant care products grew by 10% and 30% respectively, sales of fertilizers remained at the same level, while sales of agricultural machinery increased by 46%. Grain preparation and farm equipment installation projects generated more than two times higher revenue than in previous year.

Agricultural companies produced 32% more crop production due to favorable growing season and 1% more milk than in the same period last year due to their production efficiency. Their sales revenue increased by 21% to EUR 20 million, and the operating profit of this business, including profit gained from the sale of the land holding companies, amounted to almost EUR 1.3 million.

The COVID-19 pandemic and the associated restrictions on the free movement of people and goods on the continent had the greatest impact on the Group's poultry business. The HORECA sector in the Group's main markets in the Baltic and Scandinavian countries did not recover to its previous level at the beginning of the financial year, and was closed again in almost all countries in the second quarter of the financial year. The result has been overproduction of poultry meat across the EU and falling prices, while prices for cereals and feedstuffs have risen to incredible heights. Revenue from poultry business decreased by 9% to EUR 35 million and business was profitless. No significant recovery of this business is forecasted this financial year.

Mažvydas Šileika, Finance Director of AB Linas Agro Group
Mob. +370 619 19 403
E-mail m.sileika@linasagro.lt

ENCL:
AB Linas Agro Group Consolidated unaudited Financial Statements and Interim Activity Report for the six months period ended 31 December 2020

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab19.4.2021 08:30:00 CEST | Press release

Phase IIa trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021 Lund Sweden, April 19, 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of the tumor targeted superantigen naptumomab estafenatox (Naptumomab). The Phase IIa open label trial will evaluate naptumomab in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non-small cell lung cancer. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, pharmacokinetics and pharmacodynamics. Naptumomab treatment regimens have demonstrated preliminary safety and anti-tumor activity in early-stage clinical trials in solid tumors. Naptumomab binds a genetically enginee

Active Biotech och NeoTX tillkännager IND-godkännande från FDA för klinisk fas II-studie med naptumomab19.4.2021 08:30:00 CEST | Pressemelding

En fas IIa-studie i icke-småcellig lungcancer förväntas starta rekrytering i USA under andra halvåret 2021 Lund, 19 april 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) och NeoTX tillkännager idag att man har erhållit godkännande av en Investigational New Drug-ansökan (IND) från amerikanska läkemedelsverket Food and Drug Administration (FDA) för det tumörriktade superantigenet naptumomab estafenatox (naptumomab). Den öppna fas IIa-studien kommer att utvärdera naptumomab i kombination med docetaxel i 35 patienter med avancerad eller metastaserad icke-småcellig lungcancer och som är förbehandlade med checkpoint-hämmare. Det primära målet är objektiv responsfrekvens mätt med RECIST 1.1-kriterier. Studien kommer också att utvärdera säkerhet, responsduration, progressionsfri överlevnad, farmakokinetik och farmakodynamik. Behandlingsregimer för naptumomab har visat preliminär säkerhet och antitumöraktivitet i tidiga kliniska studier i patienter med solida tumörer. Naptumomab binder

Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May19.4.2021 08:00:00 CEST | Press release

Press Release 19 April 2021 Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP-001, at the following upcoming scientific conferences: Neoantigen Summit Europe, April 20 – 22, 2021 Alex Karlsson-Parra, Chief Scientific Officer at Immunicum, will make an oral presentation on “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, on Wednesday, April 21st at 2:45 pm CET / 8:45 am ET. Cancer Immunotherapy (CIMT) Annual Meeting, May 10 – 12, 2021. Alex Karlsson-Parra will deliver an oral presentation on “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a

Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj19.4.2021 08:00:00 CEST | Pressemelding

Pressrelease 19 april 2021 Immunicum tillkännager presentationer vid kommande vetenskapliga möten i april och maj Immunicum AB (publ) meddelade idag att bolaget kommer att delta och göra ett flertal presentioner gällande sina två program i klinisk fas II-utveckling, immunprimern ilixadencel och canceråterfallsvaccinet DCP-001 vid nedanstående vetenskapliga möten: Neoantigen Summit Europe, 20 – 22 april, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat ” “Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines”, onsdagen den 21 april kl. 14.45 CET/8.45 ET. Cancer Immunotherapy (CIMT) Annual Meeting, 10-12 maj, 2021 Alex Karlsson-Parra, Chief Scientific Officer, Immunicum håller ett anförande på temat “Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a

ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands19.4.2021 07:30:00 CEST | Press release

ABN AMRO accepted settlement offer in the anti-money laundering investigation in the Netherlands Today ABN AMRO Bank N.V. (ABN AMRO) announced that it has accepted a settlement offer from the Dutch Public Prosecution Service (DPPS) in connection with the previously announced investigation by the DPPS into ABN AMRO's compliance with its obligations under the Dutch Anti-Money Laundering and Counter Terrorism Financing Act (Wet ter voorkoming van witwassenen financiering van terrorisme, AML/CTF Act) between 2014 and 2020. As part of this settlement, ABN AMRO will pay EUR 480 million. ABN AMRO fully cooperated with the DPPS throughout the investigation. Based on the investigation, the DPPS identified serious shortcomings in ABN AMRO's processes to combat money laundering in the Netherlands, such as the client acceptance, transaction monitoring and client exit processes (the so-called 'Client Life Cycle' processes) in the period between 2014 and 2020, as a result of which, in certain instan

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States19.4.2021 07:02:32 CEST | Press release

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as am